This study looks at the best chemotherapy for colon cancer patients based on a blood test called circulating tumor DNA (ctDNA). This test checks for tiny amounts of cancer cells in the blood after surgery. If no ctDNA is found, the risk of cancer coming back is lower, and extra treatment might not be needed. If ctDNA is found, it means a higher risk, and the best treatment plan isn't clear yet.

To join the study, patients must have had surgery to remove colon cancer and meet certain health criteria. The study will help doctors decide if extra chemotherapy is needed based on ctDNA results. The study involves blood tests and possibly more treatment based on test results.

• Study duration can be up to several months, including follow-ups.
• Participants may undergo additional blood tests for ctDNA.
• There may be risks or side effects from chemotherapy.

It's important to discuss with your doctor about the potential benefits and risks before joining the study. This study aims to improve future colon cancer treatments by understanding who might benefit from extra chemotherapy.